Cel The actual view of cellular transformation and cancer progression supports the notion that cancer cells must undergo metabolic reprogramming in order to survive in a hostile environment. This field has experienced a renaissance in recent years, with the discovery of cancer genes regulating metabolic homeostasis, in turn being accepted as an emergent hallmark of cancer. Prostate cancer presents one of the highest incidences in men mostly in developed societies and exhibits a significant association with lifestyle environmental factors. Prostate cancer recurrence is thought to rely on a subpopulation of cancer cells with low-androgen requirements, high self-renewal potential and multidrug resistance, defined as cancer-initiating cells. However, whether this cancer cell fraction presents genuine metabolic properties that can be therapeutically relevant remains undefined. In CancerMetab, we aim to understand the potential benefit of monitoring and manipulating metabolism for prostate cancer prevention, detection and therapy. My group will carry out a multidisciplinary strategy, comprising cellular systems, genetic mouse models of prostate cancer, human epidemiological and clinical studies and bioinformatic analysis. The singularity of this proposal stems from the approach to the three key aspects that we propose to study. For prostate cancer prevention, we will use our faithful mouse model of prostate cancer to shed light on the contribution of obesity to prostate cancer. For prostate cancer detection, we will overcome the consistency issues of previously reported metabolic biomarkers by adding robustness to the human studies with mouse data integration. For prostate cancer therapy, we will focus on a cell population for which the metabolic requirements and the potential of targeting them for therapy have been overlooked to date, that is the prostate cancer-initiating cell compartment. Dziedzina nauki medical and health sciencesclinical medicineoncologyprostate cancermedical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistancemedical and health sciencesbasic medicinephysiologyhomeostasismedical and health scienceshealth sciencesnutritionobesity Program(-y) FP7-IDEAS-ERC - Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Temat(-y) ERC-SG-LS4 - ERC Starting Grant - Physiology, Pathophysiology and Endocrinology Zaproszenie do składania wniosków ERC-2013-StG Zobacz inne projekty w ramach tego zaproszenia System finansowania ERC-SG - ERC Starting Grant Instytucja przyjmująca ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS Wkład UE € 1 498 686,00 Adres PARQUE TECNOLOGICO EDIFICIO 801 A 48160 Derio Vizcaya Hiszpania Zobacz na mapie Region Noreste País Vasco Bizkaia Rodzaj działalności Research Organisations Kierownik naukowy Arkaitz Carracedo Perez (Dr.) Kontakt administracyjny Alfonso Egaña Barrenechea (Mr.) Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Koszt całkowity Brak danych Beneficjenci (1) Sortuj alfabetycznie Sortuj według wkładu UE Rozwiń wszystko Zwiń wszystko ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOCIENCIAS Hiszpania Wkład UE € 1 498 686,00 Adres PARQUE TECNOLOGICO EDIFICIO 801 A 48160 Derio Vizcaya Zobacz na mapie Region Noreste País Vasco Bizkaia Rodzaj działalności Research Organisations Kierownik naukowy Arkaitz Carracedo Perez (Dr.) Kontakt administracyjny Alfonso Egaña Barrenechea (Mr.) Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Koszt całkowity Brak danych
